Today is World CML Day - 9/22
TODAY IS WORLD CML DAY!
One day, one community, one life changing reality… Today we unite to take World CML Day global!
Today we are together to take a stand, share our needs and raise awareness!
Today and all week long in September organizations around the globe are celebrating World CML Day through their activities, by sharing their achievements over the past year and by pointing out the problems they are still facing.
CML ADHERENCE APP “CML Today” is celebrating its 1st birthday! “CML Today” is an app that has been developed to support adherence to TKIs as well as to track patients` PCR results. The mobile app is now available in 7 languages: English, German, French, Spanish, Portuguese, Hebrew and Arabic with more languages to follow. You can download „CML Today“ free-of-charge from the Apple App Store (iphone) and in the Google PlayStore (Android). Please talk about “CML Today” and encourage CML patients to use “CML Today”!
Please also check out the activities that are taking place all over the world on World CML Day 2016 and the campaign materials developed by members of the CML Advocates Network - and do not forget to share your activities with us and other groups! Last but not least, don´t miss our Facebook-page!
More information on World CML Day 2016 can be found here.
Tomorrow is World CML Day 2016!
... is the motto for this year´s World CML Day campaign, which will take place tomorrow, Thursday Sept 22!
One day, one community, one life changing reality…
Today, together we can make World CML Day more visible and engaging! Together we can make it global!
In order to help you spread the message of awareness and strengthen your voice, the CML Advocates Network has developed a World CML Day toolkit to make this day global and unique. The toolkit includes adaptable artwork for print and online use (posters & flyers), a photo database and a press release.
Check out our members´ campaign materials and also don´t miss our Facebook-page.
Please share photos and activities of your World CML day with us by e-mailing to , so we can add them to our list of worldwide activities and to our photo gallery.
We wish you all an inspiring and successful World CML Day 2016!
The CML Advocates Network's Clinical Trials Registry currently lists 27 CML studies
Set up and driven by CML Advocates Network, the Clinical Trials Registry provides patients with easy access to information on ongoing CML studies. Entries are updated at regular intervals: new studies and sites are added whereas completed or terminated studies are no longer shown on the registry. Currently 27 CML studies from many countries around the world are listed. The most recent additions to the registry are:
- OPTIC, a study to determine the efficacy and safety of ponatinib in patients with resistant CML in chronic phase. This study is including patients in 19 countries on five continents.
- ENESTPath Patient’s Voice Italian Substudy. This study is exploring the emotional experience of patients participating in the ENESTPath study with nilotinib. The substudy is available only in Italy.
Eleven studies are ongoing but no longer recruiting new patients. These studies have been moved to the category "Trials that are no longer recruiting".Two trials have been completed or terminated: Spirit 3 and NordDutchCML006. They are no longer ongoing and therefore not any more listed on the database.
We would like to thank everyone for sharing information with us on new studies or changes in ongoing studies. Your invaluable input helps us keep the registry up to date. Thank you.
Do you know of any study that is not yet listed in our Clinical Trial Database? Please let us know by filling out this form. Or is there an entry which should be corrected? If so, please send us an email. Please also visit our discussion forum if you have any questions or wish to share your experience on these studies!
Patient-friendly summary of ELN Treatment Recommendations for CML now available in Czech and Romanian
Including the two new translations, the summary of the treatment recommendations for people living with CML is now accessible in 22 languages: English, Arabic, Albanian, Azerbaijani, Bulgarian, Chinese (traditional and simplified), Croatian, Czech, Danish, Dutch, French, Georgian, German, Hebrew, Italian, Polish, Portuguese, Romanian, Russian, Serbian, Spanish and Turkish. Please visit the summary at http://www.cmladvocates.net/cmlsummary
We would like to thank Leny Caban from the Romanian organization „Asociatia Pacientilor cu Neoplazii Mieloproliferative - MIELOPRO” and Jana Pelouchova from the Czech organization „Diagnóza leukemie” for making our patient-friendly summary available to even more readers. Thank you very much, Leny and Jana, for dedicating your time and efforts to co-ordinating and performing the translation and review of the documents.
If your organization would like to arrange translation of the summary into your local language, please contact Jan, Giora, Nicole or Marion for advice at .
Getting ready for World CML Day 2016 on Sept 22
... is the motto for the World CML Day campaign!
One day, one community, one life changing reality…
Today, together we can make World CML Day more visible and engaging! Together we can make it global!
In order to help you spread the message of awareness and strengthen your voice, the CML Advocates Network has developed a World CML Day toolkit to make this day global and unique. The toolkit includes:
- Adaptable artwork for print and online use (posters & flyers)
- A photo database
- A press release
All material can be found here: http://www.cmladvocates.net/world-cml-day-9-22
If you are not sure how to use all these tools you can watch the training - video at http://www.cmladvocates.net/cmlhorizons/cmlhorizons2016 (Advocacy session #4).
This video contains valuable strategic information and suggestions for how to get the most out of the campaign, how to do your own campaign and learn from best practices.
If you have any questions please do not hesitate to contact Jelena at
We wish you all an inspiring and successful World CML Day 2016!
PS: Please do not forget to be creative and share the photos and activities of your World CML day with us by e-mailing to !
Report of CML Horizons 2016 in Slovenia is now available, plus all presentations and web streams!
From 6-8 May 2016, the CML Advocates Network welcomed 118 CML patient advocacy leaders from 65 countries at its global annual international conference "CML Horizons" in Ljubljana (Slovenia). Key CML experts reported about newest data on CML research, treatment and care. Leading patient advocates shared patient advocacy initiatives and best practice in areas like patient-generated evidence, fundraising, campaigning, access, generics, financial management, involvement in research and partnering with medical writers.
We have now compiled a detailed report which summarizes all presentations and discussions at CML Horizons 2016. Download the CML Horizons 2016 conference report here.
In addition, all presentations and video recordings of all sessions at CML Horizons are also available here.
Our publication in LEUKEMIA: Patients' declaration on the use of generics in CML treatment
Market exclusivity for imatinib has lapsed in 10 EU countries, most countries to follow in 2016. CML patients have been increasingly exposed to generics and copy drugs in the treatment of CML, raising concerns about outcomes when patients are switched between products for non-medical reasons.
A survey of patient organisations and physicians by the CML Advocates Network in 2013 determined that generic imatinib and dasatinib were available in 32 countries. In 2014, CML patient organizations released a declaration, calling for quality and consistency when TKI generics are prescribed, demanding data on bioequivalence and clinical equivalence to the originator drug. Patients should not be switched between products with the same substance for non-medical reasons. If a switch is enforced, it should not happen more than once a year, with sufficient follow-up assessing safety and efficacy. In case of loss of response or increase in toxicity after switching, switching to the previous treatment or another treatment should be allowed. More frequent molecular monitoring post-switch should allow early detection of differences in effectiveness or toxicity. These recommendations by the patient community may support experts' discussion on CML management with TKI generics.
Our paper has now been published in the journal LEUKEMIA, doi: 10.1038/leu.2016.220
European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016
The 21st European Hematology Association’s Congress (EHA, 9-12 June 2016) was abuzz with networking between over 10.000 participants who travelled from all over the world to Copenhagen. The EHA Congress combined sessions and a diverse range of topics around Hematology highlighting state-of-the-art clinical practice, recent advances, new data and views from different stakeholders and international organizations. A hot topic this year were the European Reference Networks (ERNs). The CML Advocates Network is actively engaged in the upcoming ERN on rare hematological diseases.
EHA Education session: The role of the immune system in maintaining remission after stopping CML treatment
In the CML Education Session at the EHA congress, Dr Mustjoki from the University of Finland was presenting about immunological predictors of successful treatment discontinuation in CML.
Lessons learned from treatment discontinuation studies are that nearly half of patients who have achieved deep molecular response at least for two years are able to discontinue TKI therapy. After discontinuation, residual CML on a very low, fluctuating PCR level has been detected in many patients. Similar issues have been observed with Interferon treatment in the 1990s where most patients had molecular evidence of residual disease despite successful discontinuation. Patients who had achieved good response on Interferon and have been able to stop therapy had increased levels of “natural killer immune cells” (NK-cells), lower levels of specific T-cells or a unique cytokine profile compared to those patients who failed stopping treatment. The immune mechanisms were also observed e.g. in the single-center study in Mannheim from 2001 where patients received imatinib and Peg-Interferon combination therapy and then subsequently stopped imatinib or both drugs.
EHA Education Session: CML in Blast Crisis – still a poorly understood, difficult to treat condition
Brian Huntly from the Cambridge Institute for medical Research, UK, was presenting about research in CML blast crisis in the CML Education Session at the EHA congress. CML in blast crisis still has a grim outlook. Life expectancy is still poor with 7-11 months, and transplant is required for long-term survival. About 10% of CML patients are still diagnosed in advanced or blast phase, and around 5-10% progress within first 10 years of Imatinib therapy due to persistence and resistance of CML stem cells, so in total around 20% of CML patients are somehow affected by blast crisis.
The biology of CML progression is still poorly understood. BCR-ABL itself seems to be genotoxic and is providing the environment for mutations. Mutational studies are still rare, many conducted with old-fashioned sequencing technologies on a small number of patients, rarely studies with genome sequencing. Collaborating mutations as highly heterogeneous. Potential drugs that ar currently in use are Sorafenib (RAF inhibitor in use in renal and hepatic cancer), PD0325901 (MEK inhibitor in use in lung cancer), GSK343-EZH2, I-BET (Myc inhibitor in use in AML, Myeloma) and Ruxolitinib (JAK1/2 inhibitor). Therefore, potential molecular targets for blast crisis are MYC, EZH2/PRC2, RAS-RAF-MEK-ERK, JAK-STAT which are being investigated.
In summary, CML progression is a rare but still catastrophic disorder which is poorly understood and very difficult to treat. Mouse models are in use to better understand the human disease and the mutational spectrum, and can inform both on biological mechanisms and development of therapies. Some drugs on the aforementioned targets are in early phase clinical testing. However, outlook is still poor so it is of key importance to prevent progression of CML into advanced phases.
-- Jan Geissler, 10 June 2016
Stopping treatment: Presentation about the state of play in stopping in the CML satellite symposium at EHA
Francois-Xavier Mahon was presenting about the current state of play in stopping CML treatment at the EHA Satellite Symposium on CML, hosted by Novartis. Here is a brief summary of Jan attending the session just now.
In terms of what we know about stopping Imatinib, Francois-Xavier Mahon presented the data of the first STIM (STop IMatinib) in France, where about 38% were able to successfully stop treatment without having detectable disease with a median follow-up of 65 months. Similar rates were observed in other STIM studies like STIM2 (50% still undetectable at 24 months), TWISTER (47% still undetectable at 24 months), A-STIM (61% without loss of MMR at 36 months), KID (59% without loss of MMR at 24 months), STOP2G-TKI (57% without loss of MMR at 24 months) and DADI (Dasatinib, 48% without PCR rise above 0,0069%), ENESTop (58% without loss of MMR) and EUROSKI (51% without molecular relapse at 24 months). So depending on therapy re-initiation criteria, across studies there seems to be roughly a 50:50 chance that stopping treatment in deep molecular response is successful.
Welcome, MOHA (Hungary) - now 109 patient organisations from 82 countries in the CML Advocates Network
We hereby proudly welcome a new member organisation in the CML Advocates Network: MOHA based in Budapest / Hungary is our second Hungarian patient organization. The CML Advocates Network now counts a total of 109 member organisations in 82 countries worldwide! See the list of CML groups in the Network on our world map.
